128th ENMC International Workshop on ‘Preclinical optimization and Phase I/II Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy’ 22–24 October 2004, Naarden, The Netherlands

This publication has 37 references indexed in Scilit:

• Toxicology of antisense therapeutics
  Toxicology and Applied Pharmacology, 2004
• Self-representation in the thymus: an extended view
  Nature Reviews Immunology, 2004
• Targeted Exon Skipping in Transgenic hDMD Mice: A Model for Direct Preclinical Screening of Human-Specific Antisense Oligonucleotides
  Molecular Therapy, 2004
• Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells
  Gene Therapy, 2004
• Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense
  American Journal of Human Genetics, 2004
• Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene
  The Journal of Gene Medicine, 2003
• Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies: Part II: clinical protocol
  Neuromuscular Disorders, 2002
• Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy
  The Journal of Gene Medicine, 2002
• Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient
  Brain & Development, 2001
• BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
  The Lancet, 1997